4th Quarter - Report

THE SMITH-FREE GROUP, LLC for TEVA PHARMACEUTICALS USA, INC.

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 2853 BLOCKING Act of 2021 (All sections of full text) H.R.5376, Build Back Better Act (All sections of full text) S. 2910, Expanding Access to Low-Cost Generics Act of 2021 (All sections of full text) Discussions regarding the approval of generic drugs Discussions regarding an educational initiative about digital healthcare Monitored the implementation of P.L.117-7, To prevent across-the-board direct spending cuts, and for other purposes Monitored Medicare and prescription drug changes

LobbyistCovered position, as disclosed
JACK S DEUSER —
JAMES C FREE —
MICHAEL A. GAFFIN —
ROBERT HICKMOTT —
TREVOR W. KOLEGO —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Vice President of the U.S.; HOUSE OF REPRESENTATIVES

Bills named: S. 2910 (117th), H.R. 2853 (117th), H.R. 5376 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.